vs

Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $28.5M, roughly 1.3× Creative Media & Community Trust Corp). On growth, Creative Media & Community Trust Corp posted the faster year-over-year revenue change (3.6% vs -57.1%). Over the past eight quarters, Creative Media & Community Trust Corp's revenue compounded faster (-8.5% CAGR vs -46.5%).

Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CMCT vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.3× larger
ORGO
$37.2M
$28.5M
CMCT
Growing faster (revenue YoY)
CMCT
CMCT
+60.7% gap
CMCT
3.6%
-57.1%
ORGO
Faster 2-yr revenue CAGR
CMCT
CMCT
Annualised
CMCT
-8.5%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CMCT
CMCT
ORGO
ORGO
Revenue
$28.5M
$37.2M
Net Profit
$-11.4M
Gross Margin
30.8%
Operating Margin
-125.6%
-185.1%
Net Margin
-125.8%
Revenue YoY
3.6%
-57.1%
Net Profit YoY
-11.4%
EPS (diluted)
$-3.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMCT
CMCT
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$28.5M
$225.6M
Q3 25
$26.2M
$150.9M
Q2 25
$29.7M
$101.0M
Q1 25
$32.3M
$86.7M
Q4 24
$27.5M
$126.7M
Q3 24
$28.6M
$115.2M
Q2 24
$34.4M
$130.2M
Net Profit
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
$-11.4M
$43.7M
Q3 25
$-12.5M
$21.6M
Q2 25
$-9.0M
$-9.4M
Q1 25
$-6.1M
$-18.8M
Q4 24
$-10.3M
$7.7M
Q3 24
$-10.4M
$12.3M
Q2 24
$-796.0K
$-17.0M
Gross Margin
CMCT
CMCT
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
CMCT
CMCT
ORGO
ORGO
Q1 26
-185.1%
Q4 25
-125.6%
28.1%
Q3 25
-47.7%
13.7%
Q2 25
-30.3%
-12.5%
Q1 25
-19.0%
-30.9%
Q4 24
-128.8%
8.1%
Q3 24
-36.9%
5.4%
Q2 24
-1.6%
-10.7%
Net Margin
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
-125.8%
19.4%
Q3 25
-47.5%
14.3%
Q2 25
-30.3%
-9.3%
Q1 25
-18.9%
-21.7%
Q4 24
-129.8%
6.1%
Q3 24
-36.3%
10.7%
Q2 24
-2.3%
-13.1%
EPS (diluted)
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
$-3.89
$0.31
Q3 25
$-23.52
$0.11
Q2 25
$-18.94
$-0.10
Q1 25
$-20.73
$-0.17
Q4 24
$97.71
$0.05
Q3 24
$-305.04
$0.09
Q2 24
$-98.64
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMCT
CMCT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$15.4M
$91.4M
Total DebtLower is stronger
$509.8M
Stockholders' EquityBook value
$265.4M
Total Assets
$859.2M
$520.0M
Debt / EquityLower = less leverage
1.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMCT
CMCT
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$15.4M
$93.7M
Q3 25
$17.3M
$63.7M
Q2 25
$27.8M
$73.1M
Q1 25
$19.8M
$110.0M
Q4 24
$20.3M
$135.6M
Q3 24
$18.5M
$94.3M
Q2 24
$29.3M
$89.9M
Total Debt
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
$509.8M
Q3 25
$527.8M
Q2 25
$535.6M
Q1 25
$512.7M
Q4 24
$505.7M
Q3 24
$478.3M
$62.3M
Q2 24
$485.1M
$63.8M
Stockholders' Equity
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
$265.4M
$300.1M
Q3 25
$281.9M
$255.1M
Q2 25
$287.1M
$233.2M
Q1 25
$293.0M
$242.9M
Q4 24
$304.5M
$262.9M
Q3 24
$321.0M
$278.5M
Q2 24
$351.1M
$263.5M
Total Assets
CMCT
CMCT
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$859.2M
$598.7M
Q3 25
$871.8M
$509.8M
Q2 25
$885.0M
$461.1M
Q1 25
$882.3M
$467.4M
Q4 24
$889.6M
$497.9M
Q3 24
$868.0M
$446.3M
Q2 24
$891.2M
$443.2M
Debt / Equity
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
1.92×
Q3 25
1.87×
Q2 25
1.87×
Q1 25
1.75×
Q4 24
1.66×
Q3 24
1.49×
0.22×
Q2 24
1.38×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMCT
CMCT
ORGO
ORGO
Operating Cash FlowLast quarter
$5.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
$5.8M
$39.4M
Q3 25
$3.7M
$3.1M
Q2 25
$-2.5M
$-32.9M
Q1 25
$1.2M
$-19.9M
Q4 24
$17.0M
$10.9M
Q3 24
$10.3M
$8.7M
Q2 24
$3.9M
$4.7M
Free Cash Flow
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
CMCT
CMCT
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons